Click here to close now.

Welcome!

.NET Authors: Pat Romanski, Elizabeth White, Liz McMillan, Jaynesh Shah, Carmen Gonzalez

News Feed Item

Transcept Pharmaceuticals Reports Third Quarter 2012 Financial Results

Conference call scheduled for 4:30 PM Eastern time today

POINT RICHMOND, Calif., Nov. 12, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three and nine months ended September 30, 2012.

Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product and is being marketed in the United States by Purdue Pharmaceutical Products L.P. (Purdue) under the terms of a collaboration agreement between Transcept and Purdue.

Transcept reported cash, cash equivalents and marketable securities of $98.7 million at September 30, 2012, which included the receipt of a $10.0 million milestone payment from Purdue.

"As the Intermezzo launch advances, Purdue continues to refine their understanding of the insomnia landscape and reshape the substantial Intermezzo promotional effort now underway," stated Glenn A. Oclassen, President and Chief Executive Officer of Transcept. "It is clear that further effort is needed to educate physicians and patients about middle of the night awakenings as an important manifestation of insomnia. We are working closely with Purdue to address this need and to support the future success of Intermezzo."

Three months ended September 30, 2012 financial results
Transcept recorded $10.4 million in revenue for the quarter ended September 30, 2012 compared to $0.6 million for the quarter ended September 30, 2011. Revenue during the quarter ended September 30, 2012 included a $10.0 million milestone payment from Purdue for the listing of a Transcept method of use patent in the FDA's Orange Book, $0.2 million of royalties based on Purdue net sales of Intermezzo to wholesalers, and $0.2 million from Purdue for a non-refundable option to negotiate for the commercialization of Intermezzo in Mexico and Canada. Revenue for the same period in 2011 consisted of $0.6 million of license fees for recognition of a portion of the $25.0 million up-front license fee received from Purdue in connection with the collaboration agreement for commercialization of Intermezzo in the United States. All revenue from this up-front license fee was recognized by year-end 2011.

Research and development expense for the quarter ended September 30, 2012 was $3.1 million, compared to $2.7 million for the same period in 2011. Research and development expense in both periods was primarily attributable to expense associated with our Phase 2 study for the TO-2061 development program. Research and development expense for the quarter ended September 30, 2011 included $0.5 million of severance and benefit continuation expense related to the reduction in force announced in July 2011. Research and development expense included non-cash stock compensation expense of $0.2 million for each of the quarters ended September 30, 2012 and 2011.

General and administrative expense for the quarter ended September 30, 2012 was $2.5 million, compared to $2.9 million for the same period in 2011. The decrease in general and administrative expense was primarily attributable to $0.5 million of severance and benefit continuation expense recorded in the quarter ended September 30, 2011 related to the reduction in force announced in July 2011. General and administrative expense included non-cash stock compensation expense of $0.5 million for each of the quarters ended September 30, 2012 and 2011.

Net income for the quarter ended September 30, 2012 was $4.9 million, or $0.26 per share (basic) and $0.25 per share (diluted), compared to a net loss of $5.0 million, or $0.37 per share (basic and diluted), for the same period in 2011. This increase in net income was primarily attributable to the $10.0 million method of use patent milestone payment related to the Purdue collaboration agreement. The weighted average shares used to calculate basic and diluted net income per share were 18,567,833 and 19,231,656, respectively, for the quarter ended September 30, 2012. The weighted average shares used to calculate basic and diluted net loss per share for the quarter ended September 30, 2011 were 13,521,965. At September 30, 2012, there were 18,578,159 common shares outstanding and 3,313,751 common shares underlying outstanding options and warrants.

Nine months ended September 30, 2012 financial results
Transcept recorded $10.9 million in revenue for the nine month period ended September 30, 2012 compared to $6.9 million for the nine month period ended September 30, 2011. Revenue during the nine month period ended September 30, 2012 included a $10.0 million milestone payment from Purdue for the listing of a Transcept method of use patent in the FDA's Orange Book, $0.7 million of royalties based on Purdue net sales of Intermezzo to wholesalers, and $0.2 million from Purdue for a non-refundable option to negotiate for the commercialization of Intermezzo in Mexico and Canada. Revenue for the same period in 2011 consisted of $6.9 million of license fees for recognition of a portion of the $25.0 million up-front license fee received from Purdue in connection with the collaboration agreement for commercialization of Intermezzo in the United States. All revenue from this up-front license fee was recognized by year-end 2011.

Research and development expense for the nine months ended September 30, 2012 was $8.3 million, compared to $7.9 million for the same period in 2011. Research and development expense in both periods was primarily attributable to expense associated with our Phase 2 study for the TO-2061 development program. Research and development expense for the nine months ended September 30, 2011 included severance and benefit continuation expense of $0.5 million related to our July 2011 reduction-in-force. Research and development expense included non-cash stock compensation expense of $0.7 million for the nine months ended September 30, 2012 and $0.5 million for the nine months ended September 30, 2011.

General and administrative expense for the each of the nine months ended September 30, 2012 and 2011 was $8.0 million. General and administrative expense during the nine months ended September 30, 2011 included $0.5 million severance and benefit continuation expense related to our July 2011 reduction-in-force as well as non-cash stock compensation expense of $0.2 million for stock option modifications to two members of our Board of Directors. General and administrative expense during the nine months ended September 30, 2012 included increased expense for external professional fees, including third-party consulting, and market research. General and administrative expense included non-cash stock compensation expense of $1.5 million and $1.6 million for the nine months ended September 30, 2012 and 2011, respectively.

Net loss for the nine months ended September 30, 2012 was $5.5 million, or $0.33 per share (basic and diluted), compared to a net loss of $9.2 million, or $0.68 per share (basic and diluted), for the nine months ended September 30, 2011. The decrease in net loss was primarily attributable to the $10.0 million method of use patent milestone payment related to the Purdue collaboration agreement. The weighted average shares used to calculate basic and diluted net loss per share were 16,523,037 and 13,490,588 for the nine months ended September 30, 2012 and September 30, 2011, respectively.

FINANCIAL TABLES FOLLOW

Conference call and webcast information
Transcept will host a conference call and webcast on Monday, November 12, 2012, at 4:30 p.m. ET to discuss third quarter 2012 financial results. Telephone numbers for the live conference call are 877-638-4558 (U.S.) or 914-495-8537 (International). The webcast can be accessed on the Investors page of the Transcept website at www.transcept.com and will be available for replay until close of business on January 30, 2013.

About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.IntermezzoRx.com.

Forward looking statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenues, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the following: Purdue refining their understanding of the insomnia landscape; Purdue reshaping the current Intermezzo promotional effort; the need to educate the medical community about middle-of-the-night sleep problems, and our collaboration with Purdue to educate physicians and payers accordingly; and the progression of the commercialization of Intermezzo, including our collaboration with Purdue to support any future success of Intermezzo. Transcept may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Transcept makes, including the following: achieving acceptance of Intermezzo by physicians, patients and third party payers; supplying sufficient quantities of Intermezzo from third party manufacturers and suppliers to meet anticipated market demand; the impact of competitive products and the market for Intermezzo generally; our dependence on our collaboration with Purdue; and obtaining, maintaining and protecting regulatory exclusivity and intellectual property protection for Intermezzo; and the ability of Transcept to obtain additional funding, if needed, to support its business activities. These and other risks are described in greater detail in the "Risk Factors" section of Transcept periodic reports filed with the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments Transcept may enter into or make. Transcept does not assume any obligation to update any forward-looking statements, except as required by law.

Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Senior Director, Corporate Communications
(510) 215-3567
[email protected]

 

 

Transcept Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share data)

(Unaudited)



Three Months Ended September 30, 


Nine Months Ended September 30, 


2012


2011


2012


2011

Revenue:









Royalty revenue

$    190


$          -


$     683


$          -


License fee revenue

-


625


-


6,875


Milestone revenue

10,000


-


10,000


-


Other revenue

250


-


250


-

Total revenue

10,440


625


10,933


6,875









Operating expense:









Research and development

3,057


2,668


8,273


7,922


General and administrative

2,483


2,919


7,998


8,045

Total operating expense

5,540


5,587


16,271


15,967

Income (loss) from operations

4,900


(4,962)


(5,338)


(9,092)

Interest and other income (expense), net

(45)


(29)


(124)


(84)

Net income (loss)

$ 4,855


$ (4,991)


$ (5,462)


$ (9,176)









Net income (loss) per share:








   Basic

$   0.26


$   (0.37)


$   (0.33)


$   (0.68)

   Diluted

$   0.25


$   (0.37)


$   (0.33)


$   (0.68)









Weighted average shares outstanding








   Basic

18,568


13,522


16,523


13,491

   Diluted

19,232


13,522


16,523


13,491









Comprehensive income (loss)

$ 4,862


$ (4,996)


$ (5,485)


$ (9,142)

 

 

 

Transcept Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(unaudited, in thousands)








September 30,


December 31,



2012


2011

Assets




Current assets:





Cash and cash equivalents

$          70,037


$         10,659


Marketable securities

28,634


51,703


Other current assets

2,548


3,475

Total current assets

101,219


65,837

Property and equipment, net

166


314

Goodwill

2,962


2,962

Other assets

-


38

Total assets

$        104,347


$         69,151






Liabilities and stockholders' equity 




Total current liabilities

$            3,369


$           3,339

Total non-current liabilities

-


60

Total liabilities

3,369


3,399

Stockholders' equity:





Common stock and additional paid-in capital

206,528


165,817


Accumulated deficit

(105,556)


(100,094)


Accumulated other comprehensive income 

6


29


Total stockholders' equity 

100,978


65,752

Total liabilities and stockholders' equity 

$        104,347


$         69,151

 

SOURCE Transcept Pharmaceuticals, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
One of the biggest impacts of the Internet of Things is and will continue to be on data; specifically data volume, management and usage. Companies are scrambling to adapt to this new and unpredictable data reality with legacy infrastructure that cannot handle the speed and volume of data. In his session at @ThingsExpo, Don DeLoach, CEO and president of Infobright, will discuss how companies need to rethink their data infrastructure to participate in the IoT, including: Data storage: Understanding the kinds of data: structured, unstructured, big/small? Analytics: What kinds and how responsiv...
17th Cloud Expo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterprises are using some form of XaaS – software, platform, and infrastructure as a service.
The Workspace-as-a-Service (WaaS) market will grow to $6.4B by 2018. In his session at 16th Cloud Expo, Seth Bostock, CEO of IndependenceIT, will begin by walking the audience through the evolution of Workspace as-a-Service, where it is now vs. where it going. To look beyond the desktop we must understand exactly what WaaS is, who the users are, and where it is going in the future. IT departments, ISVs and service providers must look to workflow and automation capabilities to adapt to growing demand and the rapidly changing workspace model.
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, shared some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, deploy, and manage applications integrating voice, video and data. He is the co-founder of TeleStax, a...
The Internet of Things (IoT) promises to evolve the way the world does business; however, understanding how to apply it to your company can be a mystery. Most people struggle with understanding the potential business uses or tend to get caught up in the technology, resulting in solutions that fail to meet even minimum business goals. In his session at @ThingsExpo, Jesse Shiah, CEO / President / Co-Founder of AgilePoint Inc., showed what is needed to leverage the IoT to transform your business. He discussed opportunities and challenges ahead for the IoT from a market and technical point of vie...
Sensor-enabled things are becoming more commonplace, precursors to a larger and more complex framework that most consider the ultimate promise of the IoT: things connecting, interacting, sharing, storing, and over time perhaps learning and predicting based on habits, behaviors, location, preferences, purchases and more. In his session at @ThingsExpo, Tom Wesselman, Director of Communications Ecosystem Architecture at Plantronics, will examine the still nascent IoT as it is coalescing, including what it is today, what it might ultimately be, the role of wearable tech, and technology gaps stil...
Grow your business with enterprise wearable apps using SAP Platforms and Google Glass. SAP and Google just launched the SAP and Google Glass Challenge, an opportunity for you to innovate and develop the best Enterprise Wearable App using SAP Platforms and Google Glass and gain valuable market exposure. In his session at @ThingsExpo, Brian McPhail, Senior Director of Business Development, ISVs & Digital Commerce at SAP, outlined the timeline of the SAP Google Glass Challenge and the opportunity for developers, start-ups, and companies of all sizes to engage with SAP today.
DevOps tends to focus on the relationship between Dev and Ops, putting an emphasis on the ops and application infrastructure. But that’s changing with microservices architectures. In her session at DevOps Summit, Lori MacVittie, Evangelist for F5 Networks, will focus on how microservices are changing the underlying architectures needed to scale, secure and deliver applications based on highly distributed (micro) services and why that means an expansion into “the network” for DevOps.
The 3rd International @ThingsExpo, co-located with the 16th International Cloud Expo – to be held June 9-11, 2015, at the Javits Center in New York City, NY – is now accepting Hackathon proposals. Hackathon sponsorship benefits include general brand exposure and increasing engagement with the developer ecosystem. At Cloud Expo 2014 Silicon Valley, IBM held the Bluemix Developer Playground on November 5 and ElasticBox held the DevOps Hackathon on November 6. Both events took place on the expo floor. The Bluemix Developer Playground, for developers of all levels, highlighted the ease of use of...
We’re no longer looking to the future for the IoT wave. It’s no longer a distant dream but a reality that has arrived. It’s now time to make sure the industry is in alignment to meet the IoT growing pains – cooperate and collaborate as well as innovate. In his session at @ThingsExpo, Jim Hunter, Chief Scientist & Technology Evangelist at Greenwave Systems, will examine the key ingredients to IoT success and identify solutions to challenges the industry is facing. The deep industry expertise behind this presentation will provide attendees with a leading edge view of rapidly emerging IoT oppor...
For years, we’ve relied too heavily on individual network functions or simplistic cloud controllers. However, they are no longer enough for today’s modern cloud data center. Businesses need a comprehensive platform architecture in order to deliver a complete networking suite for IoT environment based on OpenStack. In his session at @ThingsExpo, Dhiraj Sehgal from PLUMgrid will discuss what a holistic networking solution should really entail, and how to build a complete platform that is scalable, secure, agile and automated.
SYS-CON Events announced today that Gridstore™, the leader in hyper-converged infrastructure purpose-built to optimize Microsoft workloads, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Gridstore™ is the leader in hyper-converged infrastructure purpose-built for Microsoft workloads and designed to accelerate applications in virtualized environments. Gridstore’s hyper-converged infrastructure is the industry’s first all flash version of HyperConverged Appliances that include both compute and storag...
The industrial software market has treated data with the mentality of “collect everything now, worry about how to use it later.” We now find ourselves buried in data, with the pervasive connectivity of the (Industrial) Internet of Things only piling on more numbers. There’s too much data and not enough information. In his session at @ThingsExpo, Bob Gates, Global Marketing Director, GE’s Intelligent Platforms business, to discuss how realizing the power of IoT, software developers are now focused on understanding how industrial data can create intelligence for industrial operations. Imagine ...
Hadoop as a Service (as offered by handful of niche vendors now) is a cloud computing solution that makes medium and large-scale data processing accessible, easy, fast and inexpensive. In his session at Big Data Expo, Kumar Ramamurthy, Vice President and Chief Technologist, EIM & Big Data, at Virtusa, will discuss how this is achieved by eliminating the operational challenges of running Hadoop, so one can focus on business growth. The fragmented Hadoop distribution world and various PaaS solutions that provide a Hadoop flavor either make choices for customers very flexible in the name of opti...
In the consumer IoT, everything is new, and the IT world of bits and bytes holds sway. But industrial and commercial realms encompass operational technology (OT) that has been around for 25 or 50 years. This grittier, pre-IP, more hands-on world has much to gain from Industrial IoT (IIoT) applications and principles. But adding sensors and wireless connectivity won’t work in environments that demand unwavering reliability and performance. In his session at @ThingsExpo, Ron Sege, CEO of Echelon, will discuss how as enterprise IT embraces other IoT-related technology trends, enterprises with i...
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal an...
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water, are pursuing SmartGrid initiatives that represent one of the more mature examples of SAE. We have s...
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo, June 9-11, 2015, at the Javits Center in New York City. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges. In his session at @ThingsExpo, Jeff Kaplan, Managing Director of THINKstrategies, will examine why IT must finally fulfill its role in support of its SBUs or face a new round of...
One of the biggest challenges when developing connected devices is identifying user value and delivering it through successful user experiences. In his session at Internet of @ThingsExpo, Mike Kuniavsky, Principal Scientist, Innovation Services at PARC, described an IoT-specific approach to user experience design that combines approaches from interaction design, industrial design and service design to create experiences that go beyond simple connected gadgets to create lasting, multi-device experiences grounded in people's real needs and desires.